Gilead Sciences, Inc. (GILD) and partner Merck (MRK) announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed a treatment switch to an investigational oral once-weekly combination regimen of islatravir and lenacapavir maintained viral suppression in adults at week 48.Shares of the company have risen 6.2% year to date against the industry’s decline of 1.7%.Image Source: Zacks Investment ResearchData From GILD an ...

The logo for Merck is displayed on a screen at the New York Stock Exchange on Nov. 17, 2021.Merck on Thursday said its experimental treatment designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial, bringing the company one step closer to filing for approval of the shot. The pharmaceutical giant could emerge as a new competitor in the market for treatments against RSV, which causes thousands of deaths among older Americans and hundreds of deaths amo ...

Merck (MRK) closed at $111.53 in the latest trading session, marking a +1.68% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.Coming into today, shares of the pharmaceutical company had lost 7.01% in the past month. In that same time, the Medical sector lost 3.35%, while the S&P 500 gained 4.31%.The upcoming earnings release of Merck will be of great interest to investors. The company's earning ...

There's doubtlessly some coming uncertainty for both, but the prices are right.If you want to get a good value when you invest in big pharma, it's necessary to take a look at quality companies that are going through a rough patch. Given the long product development times in the industry, with most drugs taking seven years or more to launch after entering clinical trials, periods of uncertainty can potentially last a good while.But good things tend to come to those who can wait. With that in mind, let's exam ...

Dublin, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The "Activated Polyethylene Glycol Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global activated polyethylene glycol market is expected to reach an estimated $162 million by 2030 with a CAGR of 2.4% from 2024 to 2030. The major drivers for this market are the chemical and pharmaceutical sectors are expanding quickly, rapid advancement in molecular biology and biotechnology, as well ...

Dublin, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The "Flavonoids Market Report by Type, Form, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global flavonoids market size reached US$ 1.3 Billion in 2023. Looking forward, the market is expected to reach US$ 2.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2023-2032. Flavonoid is a natural polyphenolic compound with variable phenolic structures. It is a biologically active compound that adds pigm ...

Group 1 - Merck has experienced a decline in performance since the start of summer, particularly after the company reduced its full-year profit outlook [1] - The decline follows several years of outperformance by Merck, indicating a shift in market sentiment towards the company [1] Group 2 - The article does not provide additional relevant content regarding the industry or company beyond the performance and outlook of Merck [2]

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Merck (MRK) . This company, which is in the Zacks Large Cap Pharmaceuticals industry, shows potential for another earnings beat. This pharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 6.13%. For th ...

There is mounting pressure on the company's most prized franchise.Anyone crafting a bull case for the pharmaceutical giant Merck (MRK 0.53%) should include Keytruda as the company's best asset. The cancer drug has been Merck's top-selling medicine and its biggest growth driver -- by a mile. And last year, it became the best-selling drug worldwide, taking over from the immunology superstar Humira. However, Keytruda won't hold that title forever. What will happen if Merck's most important cash cow runs into s ...

Merck (MRK) announced data from the phase III KEYFORM-007 study, which evaluated a fixed-dose combination of its anti-LAG-3 antibody, favezelimab and its blockbuster anti-PD-1 therapy, Keytruda in pre-treated patients with PD-L1 positive microsatellite stable (MSS) metastatic colorectal cancer (mCRC).The study failed to meet the primary endpoint of overall survival (OS).Year to date, shares of Merck have gained 5.2% compared with the industry’s rise of 22.8%.Image Source: Zacks Investment ResearchWhat Did M ...